THERAGENICS NAMES CHRISTINE JACOBS PRESIDENT AND C.O.O.
THERAGENICS NAMES CHRISTINE JACOBS PRESIDENT AND C.O.O. ATLANTA, July 14 /PRNewswire/ -- Theragenics Corporation (NASDAQ: THRX), a cancer therapy company based here, announced today that it had appointed Christine Jacobs, 41, president and chief operating officer. John V. Herndon will remain chairman and chief executive officer of the corporation. Jacobs, who has been serving as vice president of general sales and marketing, will also assume the position of director, filling the position vacated by Bruce Smith, who will remain as secretary, treasurer and chief financial officer of the corporation. The new Theragenics president first joined the company in 1987 as national sales manager and over the next five years was promoted first to director of general sales and marketing and then to vice president of general sales and marketing. During this period, revenues for the company's TheraSeed(R) implant for prostate cancer grew from $19,000 in 1987 to nearly $2.5 million in 1991. From 1984 to 1987, Jacobs was employed by Amersham Corporation, a leading producer of radioactive diagnostic and therapeutic medical products based in Great Britain. Theragenics Chairman John V. Herndon said Jacobs has been "instrumental" in
the "phenomenal growth" the company's TheraSeed(R) product had enjoyed in recent years. He further stated that the move emphasizes the future importance that revenue growth will continue to play in the day-to-day operations of the company.
Jacobs holds a bachelor of science from Rosemary Hill College in Buffalo, N.Y., and a masters in business administration from Georgia State University. Theragenics manufacturers and markets TheraSeed(R), a radioactive implant used predominately in the treatment of prostate cancer, the second most common cancer in men. -0- 7/14/92 /CONTACT: Bruce W. Smith of Theragenics, 404-381-8338, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/ (THRX) CO: Theragenics Corporation ST: Georgia IN: HEA SU: PER
TQ-SM -- NY019 -- 8990 07/14/92 09:50 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 14, 1992|
|Previous Article:||THE SHERWIN-WILLIAMS COMPANY REPORTS SECOND QUARTER 1992 EARNINGS RESULTS|
|Next Article:||PHLX TO BEGIN TRADING OPTIONS ON VENCOR, INC.|